Primary Care: Advances in Cardiovascular and Diabetes Management

As the treatment of cardiovascular disease continues to evolve with advances in testing, screening and available treatments this online curriculum provides the latest evidence-based, best practice recommendations to identify patients at highest risk for developing cardiovascular disease to prevent advance illness and to develop comprehensive treatment plans for recently diagnosed patients to optimize patient care. 

Obesity, cardiovascular disease prevention, hypertension management remain population health concerns for our patient populations and staying abreast of literature and its implications to treatment is an imperative for providers. 

Baptist Health CME Program’s cardiovascular disease prevention online curriculum was developed to address the educational needs of providers and employees related to the risk assessment, screening, diagnosis and treatment of cardiovascular disease. 

The primary care practitioner has the special and important responsibility to diagnose and manage patients with every category of ailment, injury and disease. This course will provide practical, evidence-based strategies to strengthen healthcare competencies. Expert faculty will explain recent advances in diagnosis, management and treatment and address compelling issues as they relate to cardiovascular disease, stable coronary artery disease, preoperative cardiovascular risk and diabetes treatment in the primary care setting.

Topics include:

  • Diabetes Mellitus: New Therapeutics in Diabetes Management
  • Stable Ischemic Heart Disease
  • Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery

Commercial Supporter

Baptist Health gratefully acknowledges the commercial support provided by Medtronic.

Target Audience

Family physicians, general internists, hospitalists, cardiologists, physician assistants, nurse practitioners, nurses, pharmacists, pharmacy technicians, dietitians and respiratory therapists.

Learning Objectives

  • Examine the expanding role of SGLT-2 Inhibitors in terms of CV risk reduction and renal outcomes.
  • Examine the role of SGLT-2 Inhibitors in the management of patients with CHF regardless of diabetes status.
  • Identify the CV benefits seen with GLP-1 Inhibitors.
  • Identify patients at risk of cardiac complications during noncardiac surgery and utilize appropriate perioperative noninvasive tests.
  • Select and adjust perioperative medical therapies to reduce risk or cardiac complications. 
  • Examine pathophysiology, presentation, and diagnosis ischemic heart disease.
  • Discuss indications for coronary revascularization with stable ischemic heart disease (SIHD).
  • Discuss the usefulness for comprehensive ‘ABCDE’ Approach for all CVD patients.
  • Examine the evidence supporting aggressive medical and lifestyle management of CVD.
Additional information
Bibliography: 
  • Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., ... & Valencia, W. M. (2023). American Association of Clinical Endocrinology consensus statement: comprehensive Type 2 diabetes management algorithm–2023 update. Endocrine Practice, 29(5), 305-340.
  • Solomon, S. D., McMurray, J. J., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., ... & Langkilde, A. M. (2022). Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine, 387(12), 1089-1098.
  • Packer, M., Butler, J., Zannad, F., Pocock, S. J., Filippatos, G., Ferreira, J. P., ... & Anker, S. D. (2021). Empagliflozin and major renal outcomes in heart failure. New England Journal of Medicine, 385(16), 1531-1533.
  • Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E., Bhatt, D. L., ... & Shaw, L. J. (2021). 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 78(22), e187-e285.
  • Neumann, F. J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J. P., Falk, V., Head, S. J., Jüni, P., Kastrati, A., Koller, A., Kristensen, S. D., Niebauer, J., Richter, D. J., Seferovic, P. M., Sibbing, D., Stefanini, G. G., Windecker, S., … ESC Scientific Document Group (2019). 2018 ESC/EACTS Guidelines on myocardial revascularization. European heart journal, 40(2), 87–165.
  • Collet, J. P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., Gale, C. P., Gilard, M., Jobs, A., Jüni, P., Lambrinou, E., Lewis, B. S., Mehilli, J., Meliga, E., Merkely, B., Mueller, C., … ESC Scientific Document Group (2021). 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European heart journal, 42(14), 1289–1367.
  • Im, Chami, Tak Kyu Oh, and In-Ae Song. "Association between use of preoperative antihypertensive medication and 90-day mortality after noncardiac surgery: a retrospective cohort study." American journal of hypertension 33.6 (2020): 534-542.
  • Halvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., Abdelhamid, M., Barbato, E., De Hert, S., de Laval, I., Geisler, T., Hinterbuchner, L., Ibanez, B., Lenarczyk, R., Mansmann, U. R., McGreavy, P., Mueller, C., Muneretto, C., Niessner, A., Potpara, T. S., Ristić, A., Sade, L. E., … ESC Scientific Document Group (2022). 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. European heart journal, 43(39), 3826–3924.
  • Williams, Bryan, et al. "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)." European heart journal 39.33 (2018): 3021-3104.
Course Summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 General certificate of attendance
  • 2.00 Florida Board of Dietitians
  • 2.00 Nurse Practitioners
  • 2.00 Florida Board of Nursing
  • 2.00 Florida Board of Pharmacy
  • 2.00 Florida Board of Respiratory Therapy
Course opens: 
01/01/2024
Course expires: 
12/31/2026

Diabetes Mellitus: New Therapeutics in Diabetes Management
Angel R. Alejandro, M.D.
Endocrinologist
Baptist Health South Florida
Miami, Florida

Stable Ischemic Heart Disease
Marcus St. John, M.D.
Interventional Cardiologist
Medical Director for Cardiac Catheterization Lab
Baptist Health Miami Cardiac & Vascular Institute
Miami, Florida

Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery
Sergui Darabant, M.D. 
Cardiologist
Baptist Health Miami Cardiac & Vascular Institute
Miami, Florida

Angel R. Alejandro, M.D., faculty for this educational activity, is an advisor for Novo Nordisk and is a member of the speakers' bureau for Lilly and Boehringer Ingerheim.  He has indicated that the presentation or discussion will not include off-label or unapproved product usage. 

Sergui Darabant, M.D., faculty for this educational activity, does not have any financial relationships with any ineligible companies* to disclose and has indicated that the presentation or discussion will not include off-label or unapproved product usage. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Marcus St. John, M.D., faculty for this educational activity, is a member of the speakers’ bureau for Zoll.  He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Elise McCormack Granja, M.D., director of this educational activity, has no relevant financial relationships with any ineligible companies* to disclose.  

Adaeze “Chika” Ohaeto, APRN, coordinator of this educational activity, has no relevant financial relationships with any ineligible companies* to disclose.  

All of the relevant financial relationships listed for these individuals have been mitigated.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.

*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 General certificate of attendance
  • 2.00 Florida Board of Dietitians
  • 2.00 Nurse Practitioners
  • 2.00 Florida Board of Nursing
  • 2.00 Florida Board of Pharmacy
  • 2.00 Florida Board of Respiratory Therapy
Please login or register for a Baptist Health CME account to take this course.

Required Hardware/Software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome
Microsoft Edge
Microsoft Edge
Safari
Safari
Moxilla Firefox
Mozilla Firefox
Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.